Assessing Risk

As researchers use ever more sophisticated technology to create a growing list of drugs, vaccines, foods, and devices, potential risks stalk the process. With print and electronic media prodding them along, scientists, policymakers, business people, and the public have to consider the downside of inventions as well as the benefits. Headlines continually trumpet health risks--fluoridation caught the public's eye in the 1950s with stories that the procedure could rot teeth and cause cancer. Today

Written byBarry Palevitz
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Headlines continually trumpet health risks--fluoridation caught the public's eye in the 1950s with stories that the procedure could rot teeth and cause cancer. Today's headlines question whether cholesterol-fighting drugs called statins increase the incidence of heart attacks and whether cyclooxygenase-2 inhibitors put arthritis patients at greater risk of the muscle-wasting disease rhabdomyolysis. Should millions of people taking these pharmaceuticals stop treatment? That depends on how much the possible side effects outweigh the drugs' benefits.

When it comes to risk, biotechnology and genetically modified (GM) foods are no stranger to controversy. Do taco chips made from genetically modified corn really cause immune reactions, from hives to anaphylactic shock? Will pollen from GM corn threaten non-target insects? Do GM plants endanger the environment by cross breeding with wild relatives, thereby spawning superweeds?

Most scientists would probably agree that answers to these questions, and therefore policy decisions based on them, require hard data. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies